で公開中です！詳しく見る

Compugen

CGEN

時価総額 $1.86億

1.96 USD

-0.12

5.77%

終値時点更新済み 10月16日 16:00 EDT

プレマーケット

時間外取引

1.99

+0.03

1.53%

1日

-5.77%

5日間

-7.98%

1か月

-18.67%

3か月

-15.88%

6か月

-32.18%

年初来

26.45%

1年

0.51%

5年間

-68.18%

10年間

-67.06%

概要： Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

従業員数： 75

ヘルスケアバイオテクノロジー

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 28.6%

ニュートラル 64.3%

ネガティブ 7.1%

ニュートラル

Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference

HOLON, ISRAEL, Oct. 6, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat at the H.C.

Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference

ポジティブ

Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets

Compugen NASDAQ: CGEN outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research during a company update event.

Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets

ニュートラル

Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript

Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript

Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript

ニュートラル

Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026

HOLON, Israel, Sept. 22, 2026 /PRNewswire/ -- Compugen Ltd.

Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026

ニュートラル

Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

HOLON, Israel, Sept. 8, 2026 /PRNewswire/ -- Compugen Ltd.

Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

ポジティブ

Zacks Investment Research

All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy

ネガティブ

Zacks Investment Research

Are Medical Stocks Lagging Compugen (CGEN) This Year?

Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Compugen (CGEN) This Year?

ポジティブ

Compugen: Better Runway Ahead Of MAIA

Compugen has improved and now has a more forgiving runway into 2029. This should carry it through MAIA's interim analysis. In my view, MAIA remains the main value driver, which is why CGEN's runway materially improves its risk-reward profile. A positive randomized readout could help validate COM701, and it would be a win for CGEN's broader PVRIG approach.

Compugen: Better Runway Ahead Of MAIA

ニュートラル

Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript

Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript

Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript

ポジティブ

Compugen Q2 Earnings Call Highlights

Compugen NASDAQ: CGEN said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash runway projected to extend into 2029.

Compugen Q2 Earnings Call Highlights

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています